Post-finasteride syndrome: a surmountable challenge for clinicians.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic methodology or new primary data.
PubMed 32033719 · doi:10.1016/j.fertnstert.2019.11.030
What was done
The author reviewed contemporary scientific and clinical literature evaluating whether post-finasteride syndrome (PFS)—a constellation of persistent sexual, neurological, physical, and mental adverse effects after finasteride or dutasteride treatment—is a causally related clinical condition or an incidental association.
What was found
The abstract reports no numerical findings, effect sizes, or counts. It notes qualitatively that across reported studies, finasteride and dutasteride use was associated with sexual dysfunction that persisted in a subset of men irrespective of age, dose, or treatment duration. Multiple studies also reported increased depression, anxiety, and suicidal ideation. The author concludes that these medications induce persistent multiorgan adverse effects in biologically or epigenetically susceptible individuals.
Why it matters
This review emphasizes the ongoing clinical challenge of persistent adverse symptoms after 5-alpha reductase inhibitor use and highlights the lack of consensus, formal recognition, and evidence-based treatments.
Limits
As a narrative review, it lacks systematic search criteria, quality appraisal, and meta-analytic pooling. The abstract highlights that primary clinical trials often suffer from inadequate harm reporting and incomplete adverse event assessments, and the proposed epigenetic mechanism remains an unverified hypothesis.
Cited by
- supports The medical literature on post-finasteride syndrome identifies symptoms including loss of libido, erectile dysfunction, decreased ejaculatory volume, penile shrinkage, Peyronie's disease, testicular reduction, gynecomastia, muscle atrophy, and depression.